Atara Biotherapeutics (ATRA) shares traded at $9.93, above the average analyst 12-month target of $9.33. The article is primarily a note on the stock crossing a consensus price target, which may prompt analyst reassessment but does not include any new fundamental operating data.
Atara Biotherapeutics (ATRA) shares traded at $9.93, above the average analyst 12-month target of $9.33. The article is primarily a note on the stock crossing a consensus price target, which may prompt analyst reassessment but does not include any new fundamental operating data.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
